Madrigal Pharmaceuticals Inc (MDGL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.93B
Last updated: Nov 17, 2026 at 4:15 PM ET
Madrigal Pharmaceuticals Inc (MDGL) Statistics
Madrigal Pharmaceuticals (MDGL) has a market cap of $9.93B and an enterprise value of $9.75B. Revenue grew 92.80% over the last 12 months from the 12 months before. It kept -10.89% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 1.75% below the market cap, as cash exceeds debt.
| Market Cap | $9.93B |
|---|---|
| Enterprise Value | $9.75B |
| Latest price (Nov 17, 2026) | $421.99 |
Key Dates
The next earnings report is expected on Feb 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 8.6x and 19.7x.
| P/S Ratio | 8.6x |
|---|---|
| Forward P/S | 6.3x |
| P/B Ratio | 19.7x |
| P/TBV Ratio | 19.9x |
Price Statistics
The stock is down 20.26% over 52 weeks and trades 10.43% below its 50-day average.
| Beta (1Y) | 0.44 |
|---|---|
| 52-Week Change | -20.26% |
| 1-Month Change | -5.61% |
| 3-Month Change | -21.88% |
| 6-Month Change | -17.55% |
| 5-Year Change | +453.52% |
| 10-Year Change | +2508.24% |
| Total Return (1Y) | -20.26% |
| Total Return (3Y CAGR) | +33.67% |
| Total Return (5Y CAGR) | +38.35% |
| Return vs SPY (1Y) | -36.07% |
| Max Drawdown (1Y) | -34.26% |
| Max Drawdown (3Y) | -34.26% |
| Sharpe Ratio (1Y) | -0.67 |
| Correlation with SPY (1Y) | 0.14 |
| 50-Day Average | $471.14 |
| 200-Day Average | $495.33 |
| 52-Week Range | $353.54 to $615.00 |
| RSI (14 Days) | 40.1 |
| Average Volume (20 Days) | 592.06K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.05x current liabilities, and total debt is 0.54x shareholder equity.
| Current Ratio | 3.05x |
|---|---|
| Quick Ratio | 2.78x |
| Debt / Equity | 0.54x |
| Interest Coverage | -4.86x |
Returns and Efficiency
Return on invested capital is -12.75% over the last 12 months, against a 5-year average of -25.19%.
| Return on Equity (ROE) | -24.80% |
|---|---|
| Return on Assets (ROA) | -10.84% |
| Return on Invested Capital (ROIC) | -12.75% |
| ROE (5Y Average) | -94.94% |
| ROA (5Y Average) | -59.17% |
| ROIC (5Y Average) | -25.19% |
| Asset Turnover | 1.02x |
| Receivables Turnover | 6.80x |
Scores
MDGL has an Altman Z-Score of 8.45, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 8.45 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $1.43B over the last 12 months.
| Revenue | $1.43B |
|---|---|
| Revenue Growth (YoY) | +92.80% |
| Gross Profit | $1.43B |
| Operating Income | -$152.65M |
| Pretax Income | -$155.46M |
| Net Income | -$155.46M |
| EBITDA | -$149.38M |
| Reported EPS (TTM) | -$4.11 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 43.84% of the $1.43B in total assets.
| Cash and Equivalents | $514.64M |
|---|---|
| Total Debt | $341.27M |
| Net Cash | $173.37M |
| Net Cash Per Share | $5.93 |
| Working Capital | $932.87M |
| Shareholder Equity | $626.94M |
| Book Value Per Share | $21.44 |
| Tangible Book Value | $619.85M |
| Tangible Book Per Share | $21.19 |
| Total Assets | $1.43B |
| Total Liabilities | $807.45M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $12.42M of capital spending, operating cash flow left -$169.43M of free cash flow.
| Operating Cash Flow | -$157.01M |
|---|---|
| Capital Expenditures | $12.42M |
| Free Cash Flow | -$169.43M |
| FCF Per Share | -$7.33 |
| Depreciation and Amortization | $6.87M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -10.69%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -10.69% |
| Pretax Margin | -10.89% |
| Net Margin | -10.89% |
| EBITDA Margin | -10.46% |
| FCF Margin | -11.87% |
Growth
| Book Value Per Share Growth (2Y CAGR) | +14.44% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +13.74% |
Dividends and Yields
MDGL does not pay a dividend. Its free cash flow yield is -1.37%.
| FCF Yield | -1.37% |
|---|---|
| Buyback Yield | -0.08% |
| Shareholder Yield | -0.08% |
Stock Splits
The last split was a 1-for-35 reverse split on Jul 25, 2016.
| Last Split Date | Jul 25, 2016 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:35 |
Peer Position
Against 8 similar companies, MDGL has the lowest P/S.
P/S RatioPeer median 17.3x
ROICPeer median -36.51%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +51.61%
| P/S Ratio | 8.6x vs 17.3x median |
|---|---|
| ROIC | -12.75% vs -36.51% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +92.80% vs +51.61% median |
Analyst Forecast
Consensus estimates put revenue growth at 51.01% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +51.01% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About MDGL
What is MDGL's market cap?
Madrigal Pharmaceuticals has a market cap of $9.93B. Its enterprise value, which adds debt and subtracts cash, is $9.75B.
How many shares of MDGL are outstanding?
Madrigal Pharmaceuticals has 29.25M shares outstanding. The count is up 2.59% from a year earlier.
Does MDGL pay a dividend?
No. Madrigal Pharmaceuticals does not pay a dividend.
How much debt does MDGL have?
Madrigal Pharmaceuticals has $341.27M of total debt and $514.64M of cash and equivalents, a net cash position of $173.37M.
MDGL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors, Government Contracts